Telemedicine use has increased substantially in recent years, in part due to the COVID-19 pandemic. 1,2 Although patients and dermatologists have become more comfortable with telemedicine and its benefits, concerns remain regarding suboptimal diagnosis and management, image quality, internet access, patient triage, uncoordinated care by direct-to-consumer companies, and insurance coverage. 3 In dermatology, issues related to the diagnosis and management of skin cancer are among the most common malpractice claims and account for the largest sums awarded. 4 Although research suggests that telemedicine has a low risk for malpractice, 1 to our knowledge, the malpractice risk associated with the use of telemedicine for the of management skin cancer has not been studied. This study sought to assess all publicly reported cases of malpractice associated with the telemedicine management of skin cancer.Methods | This database study used only publicly available data and did not involve human participants. It was therefore exempt from review by the institutional review boards at Yale University and Massachusetts General Hospital and the requirements for patient informed consent.Using previously described methodologies, 1,5 we performed a search of the LexisNexis legal case database between January 15 and February 15, 2021, for all publicly reported cases from federal and state courts. A reported case includes any judicial action of a court, including judgments, rulings, opinions, dismissals, or other official actions. We searched for cases dated from January 1, 1950, to January 1, 2021, using 36 queries derived from relevant terms, including telemedicine, malpractice, and skin cancer (Figure).One of us (A.L.F.) reviewed the reported cases for their relevance to telemedicine. Cases were excluded if they did not involve medical practice allegations or if the medical issues did not pertain to the diagnosis or management of skin cancer. Cases were not limited by medical specialty.